May 30th 2023
The approval of flotufolastat F 18 (formerly 18F-rhPSMA-7.3) in prostate cancer is based on findings from the phase 3 SPOTLIGHT and LIGHTHOUSE trials.
Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy
View More
Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy
View More
Medical Crossfire®: Why is PSMA so Effective? To Affinity and Beyond
View More
Expert Perspectives on Emerging CDK4/6 Inhibitor Strategies in Advanced Prostate Cancer Management Settings
View More
Oncology Town Hall™: Primary Investigators Present Key Abstracts in Genitourinary Malignancies from Paris
View More
Expert Illustrations & Commentaries™: The Role of Radioligand Therapy in mCRPC and How It Could Impact Your Practice in the Future
View More
Expert Illustrations & Commentaries™: The Role of Radioligand Therapy in mCRPC and How It Could Impact Your Practice in the Future
View More
Updates in Therapeutic Strategies for Metastatic Renal Cell Carcinoma: A Multidisciplinary Approach to Optimal Management of Adverse Effects, featuring Counseling Vignettes
View More
Medical Crossfire®: Key Questions on Sequencing, Radioligands, and Novel Emerging Approaches in CRPC
View More
Medical Crossfire®: Key Questions on Sequencing, Radioligands, and Novel Emerging Approaches in CRPC
View More
How Guidelines and Recent Clinical Trial Data Inform the Modern-Day Treatment of Advanced Prostate Cancer
View More
Updates in Therapeutic Strategies for Metastatic Renal Cell Carcinoma: A Multidisciplinary Approach to Optimal Management of Adverse Effects, featuring Counseling Vignettes
View More
Medical Crossfire®: Key Questions on Sequencing, Radioligands, and Novel Emerging Approaches in CRPC
View More
Medical Crossfire®: Key Questions on Sequencing, Radioligands, and Novel Emerging Approaches in CRPC
View More
How Guidelines and Recent Clinical Trial Data Inform the Modern-Day Treatment of Advanced Prostate Cancer
View More
How the Experts Treat NMIBC During a BCG Shortage—Integrating Recent Approvals and Investigational Therapies
View More
Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy
View More
Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy
View More
Expert Perspectives on Emerging CDK4/6 Inhibitor Strategies in Advanced Prostate Cancer Management Settings
View More
7th Annual New York Cardio-Endo-Renal Collaborative (NY CERC)
10/21/2023
View More
Oncology Town Hall™: Primary Investigators Present Key Abstracts in Genitourinary Malignancies from Paris
View More
Expert Illustrations & Commentaries™: The Role of Radioligand Therapy in mCRPC and How It Could Impact Your Practice in the Future
View More
Expert Illustrations & Commentaries™: The Role of Radioligand Therapy in mCRPC and How It Could Impact Your Practice in the Future
View More
7th Annual New York Cardio-Endo-Renal Collaborative (NY CERC)
10/21/2023
View More